1![*** Drug Safety Alert *** Xarelto (Rivaroxaban) Tablets FDA MedWatch - August 2013 Safety Labeling Changes with revisions to Prescribing Information [PostedThe MedWatch August 2013 Safety Labeling Changes po *** Drug Safety Alert *** Xarelto (Rivaroxaban) Tablets FDA MedWatch - August 2013 Safety Labeling Changes with revisions to Prescribing Information [PostedThe MedWatch August 2013 Safety Labeling Changes po](https://www.pdfsearch.io/img/74a5a5684462ce14cc2b707e1cc5998c.jpg) | Add to Reading ListSource URL: www.icsi.org- Date: 2013-10-22 15:16:09
|
---|
2![Microsoft Word - frommtg draft uspi xarelto rivaroxaban.doc Microsoft Word - frommtg draft uspi xarelto rivaroxaban.doc](https://www.pdfsearch.io/img/776eee2b26b0d513805672b706ea3556.jpg) | Add to Reading ListSource URL: www.xareltohcp.com- Date: 2016-09-08 14:47:07
|
---|
3![MEDICATION GUIDE XARELTO® (zah-REL-toe) (rivaroxaban) tablets Read this Medication Guide before you start taking XARELTO and each time you get a refill. There may be new information. This Medication Guide does not take MEDICATION GUIDE XARELTO® (zah-REL-toe) (rivaroxaban) tablets Read this Medication Guide before you start taking XARELTO and each time you get a refill. There may be new information. This Medication Guide does not take](https://www.pdfsearch.io/img/263bcf9b40f69fb0c910ed46bcf1279a.jpg) | Add to Reading ListSource URL: www.fda.gov |
---|
4![Atrial Fibrillation (AFib) Treatment Adherence Following your treatment plan will reduce your risk of AFib-related stroke. it can enter the bloodstream and cause a stroke. A stroke means Atrial Fibrillation (AFib) Treatment Adherence Following your treatment plan will reduce your risk of AFib-related stroke. it can enter the bloodstream and cause a stroke. A stroke means](https://www.pdfsearch.io/img/4ce6a6f8f980c945cadd02008d1a9dc3.jpg) | Add to Reading ListSource URL: resources.hrsonline.orgLanguage: English - Date: 2015-09-09 14:29:44
|
---|
5![QuarterWatch Monitoring FDA MedWatch Reports Why Reports of Serious Adverse Drug Events Continue to Grow October 3, 2012 Data from 2012 Quarter 1 QuarterWatch Monitoring FDA MedWatch Reports Why Reports of Serious Adverse Drug Events Continue to Grow October 3, 2012 Data from 2012 Quarter 1](https://www.pdfsearch.io/img/eb59f037a5f50ecddd6a8c899d96befe.jpg) | Add to Reading ListSource URL: www.ismp.orgLanguage: English - Date: 2012-10-03 12:53:27
|
---|
6![SPECIAL AUTHORIZATION REQUEST FORM The Newfoundland and Labrador Prescription Drug Program (NLPDP) Venous Thromboembolism (VTE) Prevention Following Surgery Pharmaceutical Services Department of Health and Community Serv SPECIAL AUTHORIZATION REQUEST FORM The Newfoundland and Labrador Prescription Drug Program (NLPDP) Venous Thromboembolism (VTE) Prevention Following Surgery Pharmaceutical Services Department of Health and Community Serv](https://www.pdfsearch.io/img/db59b98300201910c2e78a609662aea9.jpg) | Add to Reading ListSource URL: www.health.gov.nl.caLanguage: English - Date: 2016-02-02 08:19:44
|
---|
7![SPECIAL AUTHORIZATION REQUEST FORM The Newfoundland and Labrador Prescription Drug Program (NLPDP) Request for Coverage of Novel Oral Anticoagulant (NOAC) for Atrial Fibrillation (AF) Pharmaceutical Services Department o SPECIAL AUTHORIZATION REQUEST FORM The Newfoundland and Labrador Prescription Drug Program (NLPDP) Request for Coverage of Novel Oral Anticoagulant (NOAC) for Atrial Fibrillation (AF) Pharmaceutical Services Department o](https://www.pdfsearch.io/img/1ee73f575cd73f1442cec526307829a2.jpg) | Add to Reading ListSource URL: www.health.gov.nl.caLanguage: English - Date: 2015-06-23 07:06:40
|
---|
8![April 21st, 2015 Kits for which Material Safety Data Sheets are not required The kits listed below are not labelled as hazardous. Considering the Regulation (EC) N° and the OSHA regulations 29 CFRg April 21st, 2015 Kits for which Material Safety Data Sheets are not required The kits listed below are not labelled as hazardous. Considering the Regulation (EC) N° and the OSHA regulations 29 CFRg](https://www.pdfsearch.io/img/42eda0f5e195ed7bdab93f28d7a24675.jpg) | Add to Reading ListSource URL: extranet.stago.comLanguage: English - Date: 2015-07-17 16:22:49
|
---|
9![SPECIAL AUTHORIZATION REQUEST Dabigatran(Pradaxa®), Rivaroxaban(Xarelto®), Apixaban(Eliquis®) Fax requests toOR mail requests to PEI Pharmacare, P.O. Box 2000, Charlottetown, PE, C1A 7N8 SECTION 1 – SPECIAL AUTHORIZATION REQUEST Dabigatran(Pradaxa®), Rivaroxaban(Xarelto®), Apixaban(Eliquis®) Fax requests toOR mail requests to PEI Pharmacare, P.O. Box 2000, Charlottetown, PE, C1A 7N8 SECTION 1 –](https://www.pdfsearch.io/img/9608375912b4eebca970f1e839d433f2.jpg) | Add to Reading ListSource URL: www.gov.pe.caLanguage: English - Date: 2015-04-28 07:57:44
|
---|
10![DecemberSTROKE PREVENTION IN ATRIAL FIBRILLATION: ROLE OF THE NEWER ORAL ANTICOAGULANTS DecemberSTROKE PREVENTION IN ATRIAL FIBRILLATION: ROLE OF THE NEWER ORAL ANTICOAGULANTS](https://www.pdfsearch.io/img/d56c940d4b2b4a542ac04fceedb547d7.jpg) | Add to Reading ListSource URL: www.medicalpharmacies.comLanguage: English - Date: 2014-12-05 13:08:19
|
---|